Volume 20, Number 2—February 2014
Seven-Valent Pneumococcal Conjugate Vaccine and Nasopharyngeal Microbiota in Healthy Children
Seven-valent pneumococcal conjugate vaccine (PCV-7) is effective against vaccine serotype disease and carriage. Nevertheless, shifts in colonization and disease toward nonvaccine serotypes and other potential pathogens have been described. To understand the extent of these shifts, we analyzed nasopharyngeal microbial profiles of 97 PCV-7–vaccinated infants and 103 control infants participating in a randomized controlled trial in the Netherlands. PCV-7 immunization resulted in a temporary shift in microbial community composition and increased bacterial diversity. Immunization also resulted in decreased presence of the pneumococcal vaccine serotype and an increase in the relative abundance and presence of nonpneumococcal streptococci and anaerobic bacteria. Furthermore, the abundance of Haemophilus and Staphylococcus bacteria in vaccinees was increased over that in controls. This study illustrates the much broader effect of vaccination with PCV-7 on the microbial community than currently assumed, and highlights the need for careful monitoring when implementing vaccines directed against common colonizers.
Vaccination is one of the most effective methods to prevent infectious diseases by direct protection of persons against a specific pathogen and by eradication of these specific pathogens from the population, leading to so called herd effects or indirect protection (1). Over the past decade, a 7-valent pneumococcal conjugate vaccine (PCV-7) was introduced in national immunization programs for newborns in most high-income countries, and the newer-generation 10-valent and 13-valent vaccines are being progressively introduced in developing countries (2).
The specific serotypes of the first licensed 7-valent pneumococcal vaccine are common colonizers of the upper respiratory tract of children during the first years of life, in which these serotypes generally reside as part of the nasopharyngeal microbiota (bacterial community) (3). However, these bacteria might occasionally spread beyond this niche and cause otitis media, pneumonia, sepsis, or meningitis (4). Vaccines show effectiveness against vaccine-serotype disease, nasopharyngeal acquisition of pneumococci, and pneumococcal transmission. However, nonvaccine pneumoccal serotypes fill the vacant nasopharyngeal niche, leaving overall pneumococcal carriage similar or only temporarily decreased (5,6) and lead to a gradual increase in nonvaccine serotype disease (7). In addition, several studies have raised awareness of the replacement of vaccine serotypes in the bacterial community with other potential pathogens, such as Haemophilus influenzae and Staphylococcus aureus in carriage or disease (8–11). This replacement is likely explained by the highly interactive nature of the microbiota in the natural habitat of the specific bacterium (12).
The recent availability of high-throughput, deep-sequencing techniques has made it possible to obtain more insight in the microbiota in humans, including the not yet cultivated fraction of bacteria. These techniques have elucidated that bacteria of the human microbiota outnumber human host cells by 10-fold, and microbiota composition varies greatly between body sites and persons. Colonization is a dynamic process of interactions among microbes and between microbes and the host and result in balanced bacterial ecosystems that benefit health. Perturbations of these interactive microbial structures (e.g., by environmental change or vaccinations) alter the bacterial network structures and may thereby influence the presence and containment of other microbiota members, and these alterations have effects on health and susceptibility to disease (13,14).
Given the changes in pneumococcal serotypes, as well as well as S. aureus and H. influenzae carriage after vaccination with PCV-7 (7,8), we questioned whether the effects of PCV-7 could be even more extensive than initially believed. We therefore studied the effects of PCV-7 on the complete nasopharyngeal microbiota of healthy children in a randomized controlled trial by using deep-sequencing techniques. The study was initiated shortly before nationwide implementation of PCV-7 in the Netherlands, therefore before herd effects appeared, which enabled us to measure the direct effects of the vaccine (15).
Study Design and Population
Nasopharyngeal samples were obtained from a randomized controlled trial that studied efficacy of reduced-dose schedules of PCV-7 on pneumococcal carriage in 1,005 healthy children in the Netherlands. The methods of this trial have been described (15). In brief, participants were randomly assigned to receive 1) PCV-7 at 2 and 4 months of age (2-dose group) of age; 2) PCV-7 at 2, 4, and 11 months of age (2 + 1-dose group); or 3) no PCV-7 (unvaccinated control group).
For the present study, we selected nasopharyngeal samples of the group of children that received 3 vaccinations with PCV-7 (n = 336) and of the group of children that received no vaccinations with PCV-7 (controls) (n = 331). To avoid seasonal influences on microbiota composition (3), we selected samples from children whose first birthday was during October 2006–January 2007. To avoid interference from background DNA, only samples from those children with sufficient bacterial density at 12 and 24 months of age (i.e., samples with DNA levels ≥1 pg/µL) were selected for 454 pyrosequencing, as described (16).
Nasopharyngeal swab specimens from the controlled trial had been obtained during home visits by using a deep transnasal approach with a flexible, sterile, dry, cotton-wool swab (TranswabPernasal Plain; Medical Wire and Equipment Co., Ltd., Corsham, UK). Specimens were immediately inoculated into transswab modified Amies Medium, 483CE (Copan Diagnostics Inc., Murrieta, CA, USA), transported to the laboratory, and stored in saline within 24 h at −80°C until further analyses. All nasopharyngeal swab specimens were cultured for H. influenzae, Moraxella catarrhalis, S. aureus, and Streptococcus pneumoniae and subjected to pneumococcal serotyping (15,17,18). With each nasopharyngeal swab specimen, a questionnaire on risk factors for pneumococcal carriage in children and prior antimicrobial drug use was completed.
The randomized controlled trial (NCT00189020) was approved by an acknowledged Dutch National Ethics Committee (Stichting Therapeutische Evaluatie Geneesmiddelen) and conducted in accordance with European Statements for Good Clinical Practice, which included the provisions of the Declaration of Helsinki of 1989. Before enrollment, written informed consent was obtained from both parents of each participant.
Construction of Phylogenetic Library
The selected subset was processed for sequencing of the 16S rDNA gene; the 454 GS-FLX-Titanium Sequencer (Life Sciences, Branford, CT, USA) was used for sequencing. The 16SrDNA gene is a conserved gene with variable regions among bacteria. Therefore, sequencing of this gene enables detection of all bacteria in the microbiota, which enables discrimination between bacterial taxa. DNA was extracted and quantified by quantitative PCR specific for conserved regions of the 16S rDNA gene. A barcoded amplicon library was generated by amplification of the V5–V7 hypervariable region of this gene and sequenced unidirectional, which generated ≈1.5 million sequences. Details of the methods have been described (3,16) and are shown in the Technical Appendix [PDF - 110 KB - 9 pages]. The obtained sequences were processed and classified by using modules implemented in the Mothur V.1.20.0 software platform (19–22). This platform enables sequence classification on several taxonomic levels on the basis of evolutionary relatedness. The smallest accurate taxonomic level obtained by using 16S rDNA gene sequencing is the operational taxonomic unit (OTU), which is based on 97% similarity in nucleotide composition and enables differentiation just beyond genus level: OTUs do not always discriminate between species, and multiple OTUs might represent a specific genus, each capturing distinct lineages within it.
For each of the samples, rarefaction curves were plotted and sequence coverage was calculated by using the formula 1 – (number of OTUs with a single sequence per sample/number of samples in the study) to ensure that sufficient sequence numbers were analyzed. Sequence data were subjected to weighted UniFrac analysis by using the UniFrac module implemented in Mothur (23). The UniFrac metric is a proxy for the distance between microbial communities based on evolutionary relatedness of lineages in each sample. For all samples, we calculated the presence and relative and absolute abundance of all OTUs. The relative abundance was calculated as the proportion of sequences assigned to a specific OTU divided by the overall number of obtained sequences per sample. In addition, for the absolute abundance, we multiplied the relative abundance of an OTU by the obtained bacterial load per sample measured by quantitative PCR.
Data analyses were performed by using R version 2.7 (http://cran.r-project.org/bin/windows/base/old/2.7.1/), Excel 2011 (Microsoft, Redmond, WA, USA), and SPSS version 15.0 (SPSS Inc., Armonk, NY, USA). We used the Pearson χ2 test to compare baseline characteristics between PCV-7–vaccinated children and control children. To visualize the weighted UniFrac dendrogram in relation to metadata, we used iTOL version 2 software (24). We used univariate and multivariate linear regression models (function Im and analysis of variance in software package R) to study the effect of vaccination with PCV-7 on microbiota profiles. We adjusted for antimicrobial drug use 1 month before sampling, the presence of siblings, and daycare attendance in all multivariate linear regression models. Associations were considered statistically significant after correction for multiple testing by determining the false-discovery rate (q value 0.2). Relative effect sizes and their 95% CIs were calculated for all significant OTUs from the standardized regression coefficients of the fitted linear model, whereby 1 indicates no effect, >1 indicates higher abundance, and <1 indicates less abundance in vaccinated children than in controls.
Interindividual variability between vaccinated and control children at 12 months and 24 months of age was calculated by using Pearson correlations and tested for significance by using the Mann-Whitney U test. We used nonmetric multidimensional scaling (nMDS) to compare microbiota profiles for dissimilarities and Euclidean distances to locate each sample in a low-dimensional space. OTUs were clustered hierarchically by using average linkage and Pearson correlation. The optimal number of clusters was identified by using the Silhouette index. OTU clusters and Pearson correlations between OTUs were displayed by using Cytoscape V2.8.2 (25).
Characteristics of Study Population and Culture Results
We sequenced the nasopharyngeal microbiota of 97 children at 12 and 24 months of age who had received PCV-7 at 2, 4, and 11 months of age, and 103 controls. Similar to the main trial (15), in this subset of children, baseline characteristics were not different between PCV-7 vaccinees and controls (Table). Also, use of antimicrobial drugs was low, especially in the month before sampling, and no correlation was observed between antimicrobial drug use and vaccination with PCV-7 (partial correlation, r<–0.01).
Consistent with the main trial, vaccine serotype pneumococcal carriage decreased in PCV-7–vaccinated children. However, because of a lower number of children than in main trial and loss of statistical power, we observed only a trend toward increased carriage of nonvaccine-type pneumococci (p = 0.08) at 24 months of age. Furthermore, the increase in S. aureus carriage at 12 months of age in vaccinees observed in the main trial was not significant in this subset because of a loss of power (Table) (18,26).
Sequence and Microbiota Characteristics
We obtained 1,016,934 high-quality sequences (mean ± SD 2,561 ± 767 sequences/sample). Sequence depth was sufficient to obtain a high degree of sequence coverage for all samples (mean 0.995, median 0.996, range 0.975–1). Sequencing of nasopharyngeal microbiota identified a diverse ecosystem dominated by the well-known bacterial genera Moraxella, Streptococcus, and Haemophilus, but also Dolosigranulum and Corynebacterium (Technical Appendix [PDF - 110 KB - 9 pages] Table 1). In addition, we detected a range of lower abundant bacterial genera (424 OTUs excluding singletons), present in either many (Escherichia/Shigella, Neisseria, and Gemella spp.) or few (Sneathia and Porphyromonas spp.) children. We found that for most children, the microbiota profile was determined mostly by abundance of the 5 predominant OTUs, and did not differ in children at 12 and 24 months of age (Figure 1).
To discriminate potential pathogens in the OTU set, we correlated the culture results of the samples with the corresponding OTUs of Moraxella, Streptococcus, Haemophilus, and Staphylococcus. We observed a strong correlation between culture results and the highest ranking OTUs for the respective genera (p<0.005) (Technical Appendix [PDF - 110 KB - 9 pages] Table 2), which indicated a strong representation of these potential pathogens within these OTUs.
Nasopharyngeal Microbiota Composition in Vaccinees and Controls
To evaluate the effect of vaccination with PCV-7 on the overall microbial community composition, we first calculated the degree of dissimilarity in microbiota composition between vaccinees and controls by using nMDS (27). We observed a significant shift in microbiota profiles between vaccinated and nonvaccinated children at 12 months of age (geometric means; p = 0.01, by F-test) but not at 24 months of age (Figure 2).
Because nMDS suggested higher variability of community profiles in vaccinees, we calculated interindividual variability in microbiota composition among vaccinees and controls by using Pearson correlations. We confirmed higher interindividual variability (i.e., less similarities between profiles) among vaccinees than in control children at 12 months of age (median correlation coefficient r = 0.39 vs. 0.41, p<0.0001) than at 24 months of age (median correlation coefficient r = 0.42 vs. 0.44, p = 0.006). At 12 months of age, this variability was accompanied by a significantly higher number of OTUs per community profile (i.e., higher diversity of bacteria) in vaccinated children (median 20, range 6–82) than in unvaccinated controls (median 17, range 4–46; p = 0.002) (Technical Appendix [PDF - 110 KB - 9 pages] Table 3).
In univariate and multivariate linear regression models, these changes in overall community composition, variability, and bacterial diversity in vaccinated children were accompanied by significant (false-discovery rate q value <0.2, p<0.0003) increases in relative and absolute abundance of anaerobic bacteria (e.g., Veillonella spp., relative effect size [RES] 3.90, 95% CI 2.13–7.17; Prevotella spp., RES 7.24, 95% CI 4.06–12.94; unclassified Bacteroidetes spp., RES 2.41, 95% CI 1.28–4.54; and Leptotrichia spp., RES 3.31, 95% CI 1.78–6.16) as well as increases in relative and absolute abundance of several streptococcal OTUs (RES 4.53, 95% CI 2.48–8.30). A trend (0.005<p< 0.05) toward higher abundance of gram-positive Actinomyces spp. (RES 3.00, 95% CI 1.60–5.62) and Rothia spp. (RES 2.43, 95% CI 1.29–4.58), the gram-negative Neisseria spp. (RES 2.12, 95% CI 1.13–3.99), and the anaerobes Fusobacterium spp. (RES 1.93, 95% CI 1.02–3.64) and Megasphaera spp. (RES 1.96, 95% CI 1.03–3.71) was also observed after vaccination with PCV-7. In addition, we found apparent higher absolute abundance of Haemophilus (RES 1.33, 95% CI 0.73–2.44) and Staphylococcus (RES 1.56, 95% CI 0.83–2.93) species in vaccinated children at age 12 months (Figure 3). At 24 months of age, differences between vaccinees and controls had largely disappeared.
Although antimicrobial drug use was low, we observed a trend (0.01<p< 0.05) toward decreased relative abundance of Dolosigranulum (RES 0.28, 95% CI 0.061–1.33) and Corynebacterium (RES 0.28, 95% CI 0.061–1.30) and increased abundance of Staphylococcus (RES 6.29, 95% CI 1.38–28.77) in children who received antimicrobial drugs in the month before sampling.
Microbial Inference Network in Controls and Vaccinees
Because microbial ecosystems form interacting networks of microorganisms, the presence (or abundance) of 1 type of bacteria will most likely affect the presence of others. To obtain better insight into the effect of vaccination on the bacterial community structure, we evaluated the effect of vaccination with PCV-7 on the microbial interaction network by using network inference analysis (Figure 4). OTUs were hierarchically clustered and displayed with their Pearson correlation by using Cytoscape V2.8.2 for control (Figure 4, panel A) and vaccinated (Figure 4, panel B) children. At the age of 12 months, children showed clear shifts in cluster distribution, composition, and interrelatedness after vaccination with PCV-7. In general, as a consequence of vaccination with PCV-7, several independent clusters observed in controls merged into 1 large cluster in vaccinees: this cluster included gram-negative anaerobes (Prevotella, Veillonella, and Fusobacterium spp.) as well as Actinomyces and Neisseria spp. and several streptococcal species. Bacteria that had expanded as a consequence of vaccination all belonged to the merged cluster or a single distinct cluster containing mostly Prevotella, unclassified Bacteroidetes, Fusobacterium, Streptococcus, and Neisseria spp. (cluster 8). The cluster containing the predominating potential pathogens Staphylococcus and Haemophilus spp. in controls (cluster 1) was divided in vaccinees because of changed behavior, in particular that of the Staphylococcus spp. OTU.
The novelty of the present study was use of deep-sequencing analyses. By using these analyses, we gained a far broader insight into the effect of PCV-7 on bacterial carriage at the ecologic niche of pneumococci without restricting selection to cultivable or well-known potential pathogens. We showed that vaccination with PCV-7 has a marked effect on the complete microbiota composition of the upper respiratory tract in children. This effect goes far beyond the shifts in pneumococcal serotypes distribution (7,15) and well-known potential pathogens reported (8). Vaccination with PCV-7 resulted in a shift in bacterial community composition and structure, with an increase in presence or abundance of several anaerobes, such as Veillonella, Prevotella, Fusobacterium, and Leptotrichia species; gram-positive bacteria, such as Actinomyces and Rothia species, and nonpneumococcal streptococci; and gram-negative Neisseria species.
Shifts in newly acquired or expanded OTUs concern mainly commensal organisms that are in general more predominantly present in the oropharynx than in the nasopharynx (28,29). Because the reduction in carriage of the 7 specific pneumococcal serotypes after PCV-7 administration correlated highly with emergence and expansion of these oropharyngeal types of species, this finding might suggest that after eradication of a common colonizer, such as vaccine serotype pneumococci, momentum is created for species from surrounding regions to colonize or expand in the vacant nasopharyngeal niche. In support of this hypothesis, Tano et al. (30) reported negative associations between S. pneumoniae, particularly PCV-7 serotypes, and other streptococcal species in healthy young children. Moreover, Laufer et al. (31) reported negative associations between S. pneumoniae and the presence of Veillonella, Neisseria, Rothia, and Actinomyces spp. in nasal swab specimens from children with upper respiratory tract symptoms, a finding that is consistent with the influx pattern of bacteria we observed after vaccination with PCV-7.
In addition to this shift in microbiota profiles, we also observed increased bacterial diversity and interindividual variability after vaccination with PCV-7. This influx or outgrowth of anaerobes and other bacteria might lead to a disequilibrium with the host. These species might be at a disadvantage again when nonvaccine serotypes fill in the gap, which would lead to a restored host-microbiome equilibrium. This hypothesis could explain why we observed the strongest PCV-7 effect on microbiota in children at 12 months of age (1 month after administration of the last PCV-7 dose) and not at 24 months, because serotype replacement has already become apparent at this later time.
The mechanisms and consequences of this change in community composition and structure after vaccination with PCV-7 remain mostly speculative. In general, temporary disequilibria of bacterial composition (dysbiosis) are associated with an increased risk for disease, as has been shown for the gut (14) and oral niches (32). Moreover, the combination of some of the emerging bacteria (Veillonella, Actinomyces, Rothia, and Neisseria spp.) are associated with increased risk for otitis media (31). Nevertheless, in our study, we did not obtain samples during respiratory tract infections and were therefore unable to link observed changes in microbiota structure with susceptibility to respiratory tract infections. Therefore, short-term and long-term surveillance during health and disease seems warranted to understand the full implications of vaccine-induced changes in microbiota structure.
Although increased presence or abundance of S. aureus and H. influenzae at 12 months of age was not significant in this subset of children, we observed an increase in culture-proven S. aureus carriage in the original randomized controlled trial (18), as well as further increases in culture-proven S. aureus and H. influenzae carriage observed in surveillance studies 3–5 years after PCV-7 implementation in the Netherlands (8). These findings are consistent with negative associations between S. pneumoniae (particularly PCV-7 serotypes) and S. aureus (33,34) and H. influenzae (35–37) observed in healthy nonimmunized children. Nontypeable H. influenzae and S. aureus were also more frequently isolated from persons with acute otitis media after introduction of PCV-7 in national immunization programs (38–40), which indicates that carriage may reflect disease dynamics. Together with S. pneumoniae nonvaccine serotype replacement, these effects may further jeopardize the net health benefit of vaccinations with PCV.
Some limitations of our study should be recognized. First, this study was limited to a representative subset of the original study of 1,003 infants. Second, to avoid seasonal bias (3) in microbiota composition, we analyzed samples from only the winter season. Third, children who received antimicrobial drugs before sampling were not excluded from the analyses because only a small number of children received these drugs and we observed no correlation between antimicrobial drug use and vaccination with PCV. Furthermore, the observed associations between antimicrobial drug use and microbiota composition were also different from the vaccination effect of PCV-7.
One strength of this study was the randomized controlled study design, which enabled us to attribute changes in microbiota profiles directly to the conjugate vaccine independent of secular trends or other external confounders. Furthermore, recruitment in this study was completed well before implementation of PCV-7 in the Dutch vaccination program for newborns, and vaccine-induced changes in this randomized controlled trial setting might therefore become more apparent in the open population several years after introduction due to herd effects (5,7)
Our study indicates that vaccination against a common colonizer affects microbiota composition and structure. This finding underlines the need for more detailed understanding of microbiota dynamics and interactions between its inhabitants. Overall, because infants might be vulnerable to community disruptions and dysbiosis, we recommend that new trials, such as studies on efficacy of broader pneumococcal coverage vaccines, consider the effect of vaccination on the commensal flora in its totality instead of only on a single species.
Ms Biesbroek is an MD and PhD candidate at the Wilhelmina Children’s Hospital, University Medical Center, Utrecht, the Netherlands. Her research interests include molecular characterization and epidemiology of the microbiota in the respiratory tract in children.
We thank Elske J.M. van Gils, Gerwin D. Rodenburg, and the research team for conducting the randomized controlled trial; Jacob Bruin for organizing and supervising laboratory logistics; study and laboratory staff and collaborating institutes for their dedication to this project; and the children and their families for participating in this study.
This study was supported by the Netherlands Organization for Scientific Research (NWO-VENI grant 91610121 and ZonMw grant 91209010). The randomized controlled trial (ClinicalTrials.gov NCT00189020) was supported by the Dutch Ministry of Health.
- Rappuoli R, Miller HI, Falkow S. Medicine. The intangible value of vaccination. Science. 2002;297:937–9.
- Centers for Disease Control and Prevention (CDC). Progress in introduction of pneumococcal conjugate vaccine— worldwide, 2000–2012. MMWR Morb Mortal Wkly Rep. 2013;62:308–11 .
- Bogaert D, Keijser B, Huse S, Rossen J, Veenhoven R, van Gils E, Variability and diversity of nasopharyngeal microbiota in children: a metagenomic analysis. PLoS ONE. 2011;6:e17035.
- Bogaert D, de Groot R, Hermans PW. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis. 2004;4:144–54.
- Spijkerman J, van Gils EJ, Veenhoven RH, Hak E, Yzerman EP, van der Ende A, Carriage of Streptococcus pneumoniae 3 years after start of vaccination program, the Netherlands. Emerg Infect Dis. 2011;17:584–91 .
- Hanage WP, Finkelstein JA, Huang SS, Pelton SI, Stevenson AE, Kleinman K, Evidence that pneumococcal serotype replacement in Massachusetts following conjugate vaccination is now complete. Epidemics. 2010;2:80–4.
- Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet. 2011;378:1962–73.
- Spijkerman J, Prevaes SM, van Gils EJ, Veenhoven RH, Bruin JP, Bogaert D, Long-term effects of pneumococcal conjugate vaccine on nasopharyngeal carriage of S. pneumoniae, S. aureus, H. influenzae and M. catarrhalis. PLoS ONE. 2012;7:e39730.
- Block SL, Hedrick J, Harrison CJ, Tyler R, Smith A, Findlay R, Community-wide vaccination with the heptavalent pneumococcal conjugate significantly alters the microbiology of acute otitis media. Pediatr Infect Dis J. 2004;23:829–33.
- Casey JR, Pichichero ME. Changes in frequency and pathogens causing acute otitis media in 1995–2003. Pediatr Infect Dis J. 2004;23:824–8 .
- Casey JR, Adlowitz DG, Pichichero ME. New patterns in the otopathogens causing acute otitis media six to eight years after introduction of pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2010;29:304–9 .
- Faust K, Sathirapongsasuti JF, Izard J, Segata N, Gevers D, Raes J, Microbial co-occurrence relationships in the human microbiome. PLOS Comput Biol. 2012;8:e1002606.
- Cho I, Blaser MJ. The human microbiome: at the interface of health and disease. Nat Rev Genet. 2012;13:260–70 .
- Clemente JC, Ursell LK, Parfrey LW, Knight R. The impact of the gut microbiota on human health: an integrative view. Cell. 2012;148:1258–70.
- van Gils EJ, Veenhoven RH, Hak E, Rodenburg GD, Bogaert D, Ijzerman EP, Effect of reduced-dose schedules with 7-valent pneumococcal conjugate vaccine on nasopharyngeal pneumococcal carriage in children: a randomized controlled trial. JAMA. 2009;302:159–67.
- Biesbroek G, Sanders EA, Roeselers G, Wang X, Caspers MP, Trzciński K, Deep sequencing analyses of low density microbial communities: working at the boundary of accurate microbiota detection. PLoS ONE. 2012;7:e32942.
- van Gils EJ, Veenhoven RH, Rodenburg GD, Hak E, Sanders EA. Effect of 7-valent pneumococcal conjugate vaccine on nasopharyngeal carriage with Haemophilus influenzae and Moraxella catarrhalis in a randomized controlled trial. Vaccine. 2011;29:7595–8.
- van Gils EJM, Hak E, Veenhoven RH, Rodenburg GD, Bogaert D, Bruin JP, Effect of seven-valent pneumococcal conjugate vaccine on Staphylococcus aureus colonisation in a randomised controlled trial. PLoS ONE. 2011;6:e20229.
- Schloss PD, Westcott SL, Ryabin T, Hall JR, Hartmann M, Hollister EB, Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities. Appl Environ Microbiol. 2009;75:7537–41.
- Shendure J, Ji H. Next-generation DNA sequencing. Nat Biotechnol. 2008;26:1135–45.
- Whitman WB, Coleman DC, Wiebe WJ. Prokaryotes: the unseen majority. Proc Natl Acad Sci U S A. 1998;95:6578–83.
- Cole JR. The Ribosomal Database Project (RDP-II): previewing a new autoaligner that allows regular updates and the new prokaryotic taxonomy. Nucleic Acids Res. 2003;31:442–3.
- Lozupone C, Knight R. UniFrac: a new phylogenetic method for comparing microbial communities. Appl Environ Microbiol. 2005;71:8228–35.
- Letunic I, Bork P. Interactive Tree Of Life (iTOL): an online tool for phylogenetic tree display and annotation. Bioinformatics. 2007;23:127–8.
- Cline MS, Smoot M, Cerami E, Kuchinsky A, Landys N, Workman C, Integration of biological networks and gene expression data using Cytoscape. Nat Protoc. 2007;2:2366–82.
- van Gils EJ, Veenhoven RH, Hak E, Rodenburg GD, Keijzers WC, Bogaert D, Pneumococcal conjugate vaccination and nasopharyngeal acquisition of pneumococcal serotype 19A strains. JAMA. 2010;304:1099–106.
- Goslee SC, Urban DL. The ecodist package for dissimilarity-based analysis of ecological data. J Stat Softw. 2007;22:1–19.
- Crielaard W, Zaura E, Schuller AA, Huse SM, Montijn RC, Keijser BJ. Exploring the oral microbiota of children at various developmental stages of their dentition in the relation to their oral health. BMC Med Genomics. 2011;4:22.
- Lemon KP, Klepac-Ceraj V, Schiffer HK, Brodie EL, Lynch SV, Kolter R. Comparative analyses of the bacterial microbiota of the human nostril and oropharynx. MBio. 2010;1:e00129–10 .
- Tano K, Olofsson C, Grahn-Håkansson E, Holm SE. In vitro inhibition of S. pneumoniae, nontypable H. influenzae and M. catharralis by alpha-hemolytic streptococci from healthy children. Int J Pediatr Otorhinolaryngol. 1999;47:49–56.
- Laufer AS, Metlay JP, Gent JF, Fennie KP, Kong Y, Pettigrew MM. Microbial communities of the upper respiratory tract and otitis media in children. MBio. 2011;2:e00245–10.
- Frank DN, Zhu W, Sartor RB, Li E. Investigating the biological and clinical significance of human dysbioses. Trends Microbiol. 2011;19:427–34.
- Bogaert D, van Belkum A, Sluijter M, Luijendijk A, de Groot R, Rümke HC, Colonisation by Streptococcus pneumoniae and Staphylococcus aureus in healthy children. Lancet. 2004;363:1871–2.
- Regev-Yochay G, Dagan R, Raz M, Carmeli Y, Shainberg B, Derazne E, Association between carriage of Streptococcus pneumoniae and Staphylococcus aureus in Children. JAMA. 2004;292:716–20.
- Cobey S, Lipsitch M. Pathogen diversity and hidden regimes of apparent competition. Am Nat. 2013;181:12–24.
- Lysenko ES, Ratner AJ, Nelson AL, Weiser JN. The role of innate immune responses in the outcome of interspecies competition for colonization of mucosal surfaces. PLoS Pathog. 2005;1:e1.
- Xu Q, Almudervar A, Casey JR, Pichichero ME. Nasopharyngeal bacterial interactions in children. Emerg Infect Dis. 2012;18:1738–45.
- Veenhoven R, Bogaert D, Uiterwaal C, Brouwer C, Kiezebrink H, Bruin J, Effect of conjugate pneumococcal vaccine followed by polysaccharide pneumococcal vaccine on recurrent acute otitis media: a randomised study. Lancet. 2003;361:2189–95.
- Eskola J, Kilpi T, Palmu A, Jokinen J, Haapakoski J, Herva E, Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med. 2001;344:403–9.
- Coker TR, Chan LS, Newberry SJ, Limbos MA, Suttorp MJ, Shekelle PG, Diagnosis, microbial epidemiology, and antibiotic treatment of acute otitis media in children: a systematic review. JAMA. 2010;304:2161–9.
Suggested citation for this article: Biesbroek G, Wang X, Keijser BJF, Eijkemans RMJ, Trzciński K, Rots NY, et al. Seven-valent pneumococcal conjugate vaccine and nasopharyngeal microbiota in healthy children. Emerg Infect Dis [Internet]. 2014 Feb [date cited]. http://dx.doi.org/10.3201/eid2002.131220
1These authors contributed equally to this article.
Comments to the Authors
Comments to the EID Editors
Please contact the EID Editors via our Contact Form.
- Page created: January 17, 2014
- Page last updated: January 17, 2014
- Page last reviewed: January 17, 2014
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)